Amgen (AMGN) Tops Q1 EPS by 35c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q1 EPS of $5.15, $0.35 better than the analyst estimate of $4.80. Revenue for the quarter came in at $8.62 billion versus the consensus estimate of $8.59 billion.

GUIDANCE:

Amgen sees FY2026 EPS of $21.70-$23.10, versus the consensus of $22.30. Amgen sees FY2026 revenue of $37.1-38.5 billion, versus the consensus of $37.79 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Hinge Health signs $86M office lease in San Francisco
• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance